← Back

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

General • March 9, 2026

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis is drawing significant interest across the industry.

**media[965019]**CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin disease characterized by persistent itching, redness, and irritation. It affects around 20% of children and up to 10% of adults worldwide[1]. Though not infectious, atopic dermatitis has a profound impact on patients' quality of life due to its cyclical nature of flare-ups and remissions. Current treatments, including topical corticosteroids, biologics, and Janus kinase (JAK) inhibitors, provide symptomatic relief for many patients, but often fail to deliver sustained disease control, especially in moderate-to-severe cases. Therefore, there is an urgent need for safer, more effective, and durable treatments that address underlying disease mechanisms and improve long-term outcomes.

Experts suggest this could influence future trends and innovation in the sector.

More updates are expected as the story develops.

Related Articles

Source: Original →